CN104804077A - 胸腺肽的制备提取方法及其用药安全的产物 - Google Patents
胸腺肽的制备提取方法及其用药安全的产物 Download PDFInfo
- Publication number
- CN104804077A CN104804077A CN201510158633.XA CN201510158633A CN104804077A CN 104804077 A CN104804077 A CN 104804077A CN 201510158633 A CN201510158633 A CN 201510158633A CN 104804077 A CN104804077 A CN 104804077A
- Authority
- CN
- China
- Prior art keywords
- zadaxin
- peak
- hplc
- place
- thymosin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 36
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 229940079593 drug Drugs 0.000 title abstract description 17
- 108010046075 Thymosin Proteins 0.000 title abstract description 8
- 102000007501 Thymosin Human genes 0.000 title abstract description 8
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 title abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 238000001514 detection method Methods 0.000 claims abstract description 9
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 7
- 238000005119 centrifugation Methods 0.000 claims abstract description 4
- 238000010438 heat treatment Methods 0.000 claims abstract description 4
- 238000001728 nano-filtration Methods 0.000 claims abstract description 4
- 108010078233 Thymalfasin Proteins 0.000 claims description 66
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims description 66
- 229960004231 thymalfasin Drugs 0.000 claims description 66
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 29
- 210000001541 thymus gland Anatomy 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 22
- 230000000875 corresponding effect Effects 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- 238000002347 injection Methods 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 7
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 7
- 239000006035 Tryptophane Substances 0.000 claims description 7
- 229960004799 tryptophan Drugs 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000005516 engineering process Methods 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 3
- 244000309466 calf Species 0.000 claims description 3
- 230000002992 thymic effect Effects 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 206010019799 Hepatitis viral Diseases 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 230000002596 correlated effect Effects 0.000 claims description 2
- 230000007547 defect Effects 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 230000036737 immune function Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000001613 neoplastic effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 201000001862 viral hepatitis Diseases 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 11
- 238000001228 spectrum Methods 0.000 description 9
- 239000012043 crude product Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000284 extract Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 206010011703 Cyanosis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000000898 Thymopoietin Substances 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- -1 tincture Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57581—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510158633.XA CN104804077B (zh) | 2015-04-03 | 2015-04-03 | 胸腺肽的制备提取方法及其用药安全的产物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510158633.XA CN104804077B (zh) | 2015-04-03 | 2015-04-03 | 胸腺肽的制备提取方法及其用药安全的产物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104804077A true CN104804077A (zh) | 2015-07-29 |
CN104804077B CN104804077B (zh) | 2016-03-23 |
Family
ID=53689301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510158633.XA Active CN104804077B (zh) | 2015-04-03 | 2015-04-03 | 胸腺肽的制备提取方法及其用药安全的产物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104804077B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110496216A (zh) * | 2018-05-18 | 2019-11-26 | 山东信得科技股份有限公司 | 一种胸腺肽注射液的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1390853A (zh) * | 2002-05-16 | 2003-01-15 | 西安迪赛生物药业有限责任公司 | 一种制备胸腺肽的工艺方法 |
US20080287650A1 (en) * | 2007-03-01 | 2008-11-20 | Avi Tovi | High purity peptides |
-
2015
- 2015-04-03 CN CN201510158633.XA patent/CN104804077B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1390853A (zh) * | 2002-05-16 | 2003-01-15 | 西安迪赛生物药业有限责任公司 | 一种制备胸腺肽的工艺方法 |
US20080287650A1 (en) * | 2007-03-01 | 2008-11-20 | Avi Tovi | High purity peptides |
Non-Patent Citations (1)
Title |
---|
高思英: "胸腺肽的提取与性质研究", 《黑龙江医药》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110496216A (zh) * | 2018-05-18 | 2019-11-26 | 山东信得科技股份有限公司 | 一种胸腺肽注射液的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104804077B (zh) | 2016-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20080033430A (ko) | 혈전성 질환의 예방 또는 치료용 추출물 | |
SA04250309B1 (ar) | تركيب صيدلاني لمعالجة الأمراض القلبية وأمراض الأوعية الدموية الدماغية | |
GB2428974A (en) | Botanical drug or dietary supplement | |
JP2008502711A (ja) | 集中力及び記憶力の低下の防止又は改善のためのニンジン組成物 | |
CN101020715B (zh) | 鹿茸神经生长因子(deer ngf)提取及其制备方法 | |
TWI269656B (en) | Therapeutical composition for hepatitis C | |
KR100699790B1 (ko) | 댕댕이나무 추출물을 포함하는 간 질환 예방 및 치료효과를 가지는 약제학적 조성물 | |
CN105816471B (zh) | 一种三七总皂苷组合物及其制备方法和用途 | |
CN104804077B (zh) | 胸腺肽的制备提取方法及其用药安全的产物 | |
CN108392634A (zh) | B7s1抑制剂在制备肝癌药物中的用途 | |
CN108904533A (zh) | 牙髓间充质干细胞在制备肝硬化治疗药物中的用途 | |
CN112370496A (zh) | 枸杞叶有效成分在制备预防或治疗肝纤维化药物中的应用 | |
CN101791285A (zh) | 一种用于清除面部老年斑(脂褐素)的黄皮酰胺复合纳米乳及其制备方法 | |
CN114869928B (zh) | 用于治疗脑血管疾病的中药组合物及其用途 | |
CN108114010A (zh) | 八宝丹在制备预防早期肝癌术后复发的药物中的用途 | |
CN101054414B (zh) | 鹿茸表皮生长因子(deer egf)提取及其制备方法 | |
CN103845722A (zh) | 一种防治辐射损伤或化学药物治疗损伤的低聚肽组合物及其制备方法 | |
CN101966182A (zh) | 复方脑保护制剂及其制备方法 | |
CN111588763B (zh) | 血栓通脉药物、制备方法及含量测定方法 | |
WO2009076869A1 (zh) | 高纯度丹酚酸、制备方法及应用 | |
CN101757443A (zh) | 一种治疗血友病的中药制剂 | |
CN103845450A (zh) | 山楂在制备治疗高尿酸血症、痛风、肾功能不全药物中的应用 | |
CN104688669A (zh) | 人参皂苷浓缩型液体组方及其医药用途 | |
CN107312071A (zh) | 兴奋性神经毒性相关损伤的治疗方法 | |
CN111840306A (zh) | 川续断皂苷b在制备治疗脑卒中疾病药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20150729 Assignee: Disai Bio Pharmaceutical Co.,Ltd. Xian Assignor: Wu Jianzhong Contract record no.: 2017610000012 Denomination of invention: Method for preparing and extracting thymosin as well as product of thymosin medication safety Granted publication date: 20160323 License type: Exclusive License Record date: 20170502 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170602 Address after: Hongmiaopo Lianhu District 710016 Shaanxi city of Xi'an province No. 69 Patentee after: Disai Bio Pharmaceutical Co.,Ltd. Xian Address before: Hongmiaopo Lianhu District 710016 Shaanxi city of Xi'an province No. 69 Patentee before: Wu Jianzhong |
|
TR01 | Transfer of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation and extraction method of thymosin and its drug safe product Effective date of registration: 20220505 Granted publication date: 20160323 Pledgee: Industrial and Commercial Bank of China Limited Xi'an Lianhu road sub branch Pledgor: Disai Bio Pharmaceutical Co.,Ltd. Xian Registration number: Y2022610000218 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230612 Granted publication date: 20160323 Pledgee: Industrial and Commercial Bank of China Limited Xi'an Lianhu road sub branch Pledgor: Disai Bio Pharmaceutical Co.,Ltd. Xian Registration number: Y2022610000218 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation and extraction of Thymosin and its drug safe products Effective date of registration: 20230616 Granted publication date: 20160323 Pledgee: Industrial and Commercial Bank of China Limited Xi'an Weiyang Branch Pledgor: Disai Bio Pharmaceutical Co.,Ltd. Xian Registration number: Y2023610000455 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |